Bristol Sprycel pricing
Executive Summary
Bristol-Myers Squibb is positioning its chronic myeloid leukemia therapy Sprycel (dasatinib) as a less expensive option than high-dose Gleevec (imatinib) for second-line use in Gleevec failures. Sprycel became available within days of its June 28 accelerated approval at a price of $3,900 for a month of treatment at the recommended dosage of 140 mg/day, according to Bristol (1"The Pink Sheet" July 3, 2006, p. 5). In clinical trials, median duration of dasatinib therapy ranged from 2.8 months for lymphoid blast to 5.6 months for CML; the CML trial is ongoing. The company is detailing its multiple tyrosine kinase inhibitor to oncologists and hematologists; the oncology sales force, which has fewer than 200 reps, also details Erbitux (cetuximab)...
You may also be interested in...
Bristol Sprycel Clears FDA As First Second-Line Leukemia Agent
Bristol-Myers Squibb will be required to submit follow-up data from ongoing clinical trials to convert the accelerated approval of Sprycel for chronic myeloid leukemia to full approval, FDA said after clearing dasatinib June 28
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.